BioCentury
ARTICLE | Clinical News

RG3039: Phase Ib started

October 8, 2012 7:00 AM UTC

Repligen began a double-blind, placebo-controlled, U.S. Phase Ib trial evaluating multiple ascending-doses of oral RG3039 for 28 days in 32 healthy adult volunteers. RG3039 has Orphan Drug designation...